- Global Pharma News & Resources

Global Giant Cell Arteritis Treatment Market Analysis and Forecast Report 2021-2026: Major Players are F. Hoffmann-La Roche, Kiniksa Pharma, Teva Pharma, & Tianjin Tianyao Pharma -

DUBLIN--(BUSINESS WIRE)--The "Global Giant Cell Arteritis Treatment Market Report and Forecast 2021-2026" report has been added to's offering.

Global giant cell arteritis market growth is aided by the rising prevalence of GCA with the rapid spread of COVID-19. The market is projected to further grow at a CAGR of 5.1% between 2021 and 2026.

Giant cell arteritis (GCA) is a kind of disease that causes inflammation in the large blood vessels around the scalp, neck, and arms. It most commonly affects the around the brain at temporal arteries. The inflammation causes the arteries to narrow down and lead to poor blood flow. In addition, giant cell arteritis is an autoimmune disease that does not have a known cause, although genetic and environmental factors are said to have an impact on it. Moreover, there's a higher risk for women above 50 years affected by this disease than men. However, it rarely impacts people below 50, which suggests that the ageing process can be linked to the possible cause of GCA.

The global giant cell arteritis market is being driven by the heightened prevalence of giant cell arteritis with the rampant increase in the COVID-19 cases worldwide. Multiple researches have indicated a growth observed in the number of giant cell arteritis cases and the associated vision impairment in 2020 compared to the pre-pandemic levels.

Furthermore, since severe infections are known to be one of the major complications of immunosuppressive therapy, the outbreak of COVID-19 raised great concerns among rheumatologists. Moreover, with the growing ageing population worldwide that is more susceptible to chronic diseases, governments are increasingly investing in the development of the healthcare infrastructure to prevent the risk of mortality and permanent vision loss among GCA patients.

Similarly, leading manufacturers of treatments for giant cell arteritis, such as corticosteroids, are also increasingly devising ways to enhance their effectiveness. Therefore, the factors are estimated to significantly impact the market growth in the forecast period.

Competitive Landscape

The report looks into the market shares, plant turnarounds, capacities, investments, and mergers and acquisitions, among other major developments, of the key players in the industry.

Some of the major players in the market explored in the report are:

  • F. Hoffmann-La Roche Ltd.
  • Kiniksa Pharmaceuticals, Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Tianjin Tianyao Pharmaceutical Co., Ltd.

Key Topics Covered:

1 Preface

2 Report Coverage - Key Segmentation and Scope

3 Report Description

3.1 Market Definition and Outlook

3.2 Properties and Applications

3.3 Market Analysis

3.4 Key Players

4 Key Assumptions

5 Executive Summary

5.1 Overview

5.2 Key Drivers

5.3 Key Developments

5.4 Competitive Structure

5.5 Key Industrial Trends

6 Snapshot

6.1 Global

6.2 Regional

7 Industry Opportunities and Challenges

8 Global Giant Cell Arteritis Treatment Market Analysis

8.1 Key Industry Highlights

8.2 Global Giant Cell Arteritis Treatment Historical Market (2016-2020)

8.3 Global Giant Cell Arteritis Treatment Market Forecast (2021-2026)

8.4 Global Giant Cell Arteritis Treatment Market by Treatment Type

8.5 Global Giant Cell Arteritis Treatment Market by End Use

8.6 Global Giant Cell Arteritis Treatment Market by Region

9 Regional Analysis

9.1 North America

9.2 Europe

9.3 Asia Pacific

9.4 Latin America

9.5 Middle East and Africa

10 Market Dynamics

10.1 SWOT Analysis

10.2 Porter's Five Forces Analysis

10.3 EMR's Key Indicators for Demand

10.4 EMR's Key Indicators for Price

11 Value Chain Analysis

12 Competitive Landscape

12.1 Market Structure

12.2 Key Players

12.3 Company Profiles

13 Industry Events and Developments

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 17-Aug-2021